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ABSTRACT 
Background: Sleep difficulties may be a contributory causal factor in the occurrence of mental 
health problems. If this is true, improving sleep should benefit psychological health. Our primary 
objective was to determine whether treating insomnia leads to a reduction in paranoia and 
hallucinations. The effects on other mental health outcomes were also tested.  
Methods: For our parallel group, single blinded, explanatory randomised controlled trial (called 
OASIS), we randomised university students with insomnia to digital cognitive behaviour therapy 
for insomnia or usual practice. Online assessments were at 0, 3, 10 (post-treatment), and 22 
weeks. The primary outcomes were insomnia, paranoia, and hallucinatory experiences. The 
secondary outcomes included anxiety, depression, nightmares, and psychological well-being. 
The trial was registered (ISRCTN61272251). 
Findings: 3,755 people were randomised between 5th March 2015 to 17th February 2016. 
Compared to usual practice, the sleep intervention at 10 weeks reduced insomnia, adjusted 
difference=4.78 (95% C.I. 4.29;5.26), p<.0001, d=1.11, paranoia, adjusted difference=-2.22 
(95% C.I. -2.98;-1.45), p<.0001, d=0.19, and hallucinations, adjusted difference=-1.58 (95% C.I. 
-1.98;-1.18), p<.0001, d=0.24. Insomnia was a mediator of change in paranoia and 
hallucinations. There were improvements in other mental health outcomes. No adverse events 
were reported. 
Interpretation: This is the largest randomised controlled trial of psychological intervention for a 
mental health problem. It provides strong evidence that insomnia is a causal factor in the 
occurrence of psychotic experiences and other mental health problems. Whether the results 
generalise beyond a student population requires testing. The treatment of disrupted sleep may 
require a higher priority in mental health provision. 
Funding: Wellcome Trust. 
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INTRODUCTION 
Sleep problems are a common occurrence in patients with mental health disorders. The 
traditional view is that disrupted sleep is a symptom, consequence, or non-specific 
epiphenomenon of the disorders; the clinical result is that the treatment of sleep problems is 
given a low priority. An alternative perspective is that disturbed sleep is a contributory causal 
factor in the occurrence of many mental health disorders (1). An escalating cycle then emerges 
between the distress of the mental health symptoms, the impact on daytime functioning, and 
struggles in gaining restorative sleep. From this alternative perspective, the treatment of sleep 
problems attains a higher clinical importance. Our particular interest is in the putative causal 
relationship between disturbed sleep and psychotic experiences (2, 3). The interventionist-
causal model approach to establishing a causal relationship is to manipulate the hypothesised 
mechanistic variable and observe the effect on the outcome of interest (4); if there is a causal 
relationship then the outcome variable should alter. The effects of the manipulation can then be 
substantiated further by use of mediation analysis (5, 6). In the current study, our principal aim 
was to improve sleep in individuals with insomnia in order to determine the effect on psychotic 
experiences. This approach therefore informs both theoretical understanding and clinical 
practice. 
The most common form of sleep disruption is insomnia, comprising sustained difficulties in 
initiating and/or staying asleep that cause problems during the day. The association of insomnia 
with psychotic experiences in the general population has been convincingly established (3). 
There are multiple, independent, psychotic experiences. Each psychotic experience exists on a 
spectrum of severity in the general population with differing heritability and differing strength of 
association with insomnia (7). Paranoia and hallucinations have the strongest links with 
insomnia (2, 7, 8). However the effect of altering the level of sleep disruption, for example by 
targeted sleep treatment, on these psychotic experiences remains to be established. Clinical 
guidelines recommend the use of cognitive-behavioural therapy (CBT) as the first line treatment 
for insomnia (9). Digital forms of CBT for insomnia that require no therapist to be present have 
been shown to be efficacious as well (10, 11, 12). In patients with current delusions and 
hallucinations, our pilot randomised controlled trial has shown that insomnia can be substantially 
reduced with CBT (13), but the trial was underpowered to establish with sufficient precision the 
consequences for psychotic experiences. Therefore we wished to conduct a clinical trial that was 
large enough to test definitively the causal relationship between insomnia and self-reported 
psychotic experiences. 
In order to test thousands of individuals, we conducted an online study using a digital CBT for 
insomnia treatment. A participant pool, university students, was selected that would be easily 
reachable (since we would have access to large email lists) and at an age when mental health 
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disorders emerge. We have previously shown in a student population that sleep problems are 
associated with elevated levels of paranoia, hallucinations, anxiety, depression, and manic 
symptoms (8). Our principal objective required a comparison between the effects of a reduction 
in insomnia (in a group receiving recommended treatment) to continued sleep disruption (in a 
group likely to be receiving little or no treatment). Clear change in sleep in one group relative to 
another was required to test the mechanistic hypothesis. We were disinterested here in the 
intervention elements that may lead to change. The primary trial hypotheses were that: CBT for 
insomnia, compared to a usual practice control group, will reduce insomnia by the end of 
treatment; CBT for insomnia, compared to a usual practice control group, will reduce paranoia 
and hallucinations by the end of treatment; and that changes in insomnia will mediate the 
changes in psychotic experiences. We also took the opportunity to determine the potential 
effects of sleep improvement on a wider range of mental health outcomes in this general 
population group. Our secondary hypotheses were that digital CBT for insomnia, compared to 
usual practice, will: reduce levels of depression, anxiety, nightmares, and mania; improve 
psychological well-being; and lead to the occurrence of fewer mental health disorders. 
 
 
METHODS 
 
The OASIS (Oxford Access to Sleep Intervention for Students) trial protocol has been published 
(14). The trial was registered at Current Controlled Trials ISRCTN61272251 
(http://www.isrctn.com/ISRCTN61272251).  
 
Design 
The study was a parallel-group, superiority, explanatory randomised controlled trial of digital 
CBT versus treatment as usual (usual practice). Screening, informed consent, assessments, 
allocation to condition, and the delivery of the intervention were carried out online using an 
automated system, a specially configured instance of ‘True Colours’, an automated system for 
the scheduled collection of outcome measures (15). Participants in the control group were given 
access to the sleep intervention after their final assessment. The study received overall ethical 
approval from the University of Oxford Medical Sciences Inter-Divisional Ethics Committee and 
then local approvals at the other participating universities..  
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Participants 
The inclusion criteria were: attending university; a positive screen for insomnia, as indicated by a 
score of 16 or lower on the Sleep Condition Indicator (16); and aged 18 years or older. There 
were no exclusion criteria. 26 UK universities took part, ensuring a range in geographical 
locations and academic ability. The principal method of recruitment was the sending within 
universities of a circular email that contained a link to the web-based screening. At the 
universities where a circular email was not possible, recruitment was via advertising on websites 
and/or displaying posters. Recruitment began on the 5th March 2015 and ended on the 17th 
February 2016. Final data were collected on the 28th July 2016. Figure 1 shows the flow of 
participants. 
 
------------------------------- 
Figure 1 about here 
------------------------------- 
 
Randomisation and masking 
As recommended for large clinical trials (17), simple randomisation was used, with an allocation 
ratio of 1:1. Randomisation was carried out by the automated online system, ensuring that the 
research team was unable to influence randomisation. Participants completed all the 
assessments independently online and therefore their responses could not be influenced by the 
trial team. 
 
Assessment points 
Assessments took place at 0 (baseline), 3, 10 (end of therapy), and 22 weeks. The 3 week 
assessment comprised only the primary outcome measures in order to assess in the mediation 
analyses the temporal order of changes. Participants received an email prompt to complete the 
assessments online. The order of the assessments was consistent across time points. If 
participants did not complete the assessment then they received up to two email reminders two 
days apart. 
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Intervention 
The CBT for insomnia intervention is called Sleepio (www.sleepio.com) (11, 18). It is provided in 
six sessions, lasting an average of 20 minutes each. Sessions are unlocked weekly, although 
participants can move at a slower pace. The full program is accessible via any web browser and 
all participants start the programme online. Certain tools (e.g. sleep diaries, relaxation audios) 
could also be accessed using the web browser of a smartphone. All of the sessions, sleep 
diaries, relaxation audios, and the scheduling tool could be accessed with an iPhone. 
Completion of an initial assessment drives the algorithms that personalize the program. For 
example, the assessment leads to a tailored choice of treatment goal, with progress then 
reviewed at each subsequent session. The treatment includes behavioural, cognitive, and 
educational components. The behavioural techniques include sleep restriction (i.e. reducing the 
sleep window to enhance sleep consolidation), stimulus control (e.g. getting out of bed after 15 
to 20 minutes of wakefulness), and relaxation (e.g. tensing and relaxing muscles when in bed). 
The cognitive techniques include paradoxical intention (e.g. trying to stay awake), belief 
restructuring (e.g. targeting unrealistic expectations about sleep), mindfulness (e.g. 
acknowledging thoughts and feelings without dwelling on them), imagery (e.g. generating 
positive mental images), and putting the day to rest (e.g. setting time aside to reflect on the day). 
The educational component covers information about the processes of sleep and sleep hygiene. 
The programme is interactive, and content is presented by an animated therapist. Participants 
make a time for the session and are prompted via email/SMS if they do not ‘attend’. Participants 
complete daily sleep diaries throughout the intervention, which are used by the programme to 
tailor the advice. Sleep restriction is introduced in the third session of the course. The animated 
therapist proposes a new sleep window, which is calculated from the sleep diary data, and 
engages with the participant to help them select the timing of the window (e.g. earlier versus 
later in the night). For those reporting significant physical or other mental health problems or 
moderate to severe sleepiness then a more lenient sleep window is used. The sleep window is 
regularly reviewed. If the sleep diary data indicate a sleep efficiency of 90% or higher, the 
animated therapist advises that 15 minutes is added to the sleep window. Throughout the course 
of therapy, participants had access to a moderated online community and an online library of 
information about sleep. Participants could also view their online ‘case file’ which included four 
sections: a progress review, a reminder of strategies, an agreed sleep schedule, and a list of 
further reading. Usual practice (treatment as usual) referred to the current care that the 
participants were receiving. The level of treatment input was likely to be minimal, with 
prescription of medication for a small proportion. We did not attempt to influence the current care 
that participants received. 
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Primary outcomes 
The primary measure for insomnia was the Sleep Condition Indicator (SCI) (16). This is an eight 
item measure, validated against DSM-5 criteria, assessing sleep and its impact on daytime 
functioning over the past week. Scores can range from 0-32 with higher scores indicating better 
sleep. A clinical cut-off of less than 17 correctly identifies 89% of individuals with probable 
insomnia disorder. We used a version of the SCI that included one additional question, as a 
secondary outcome, regarding early morning waking. The internal consistency (Cronbach’s 
alpha at baseline) of the scale in the current study was .63. 
Paranoia was assessed with the Green et al Paranoid Thoughts Scale (GPTS), Part B (19). This 
scale assesses persecutory ideation, and the timeframe used was the past fortnight. The scale 
comprises 16 items, each rated on a 1 (not at all) to 5 (totally) scale. Higher scores indicate 
greater levels of paranoia. The internal consistencey of the scale in the current study was .94. 
The measure for hallucinations was the Specific Psychotic Experiences Questionnaire (SPEQ) - 
Hallucinations sub-scale (20). The scale comprises nine items rated on a 0 (not at all) to 5 (more 
than once per day) scale. The timeframe was the past fortnight. Higher scores indicate greater 
levels of hallucinatory experiences. The internal consistency of the scale in the current study 
was .93 
 
Secondary outcomes 
The secondary outcome measures for sleep were the Insomnia Severity Index (21) (Cronbach’s 
alpha in the current study = .67) and the Disturbing Dreams and Nightmare Severity Index (22) 
(Cronbach’s alpha in the current study = .91). The secondary outcome measure for psychotic 
experiences was the 16 item version of the Prodromal Questionnaire (23) (Cronbach’s alpha in 
the current study = .79). A score of 6 or more has 87% specificity and 87% sensitivity to correctly 
classify ultra-high risk for psychosis mental states in a help-seeking sample.  
The measures to assess affective symptoms were the Patient Health Questionnaire (PHQ) 9 
item version (24) (Cronbach’s alpha in the current study = .85), the Generalised Anxiety Disorder 
(GAD) 7 item version (25) (Cronbach’s alpha in the current study = .89), and the Altman Mania 
Scale (26) (Cronbach’s alpha in the current study = .64). Psychological well-being was assessed 
with the Warwick Edinburgh Mental Wellbeing Scale (27) (Cronbach’s alpha in the current study 
= .89), and the Work and Social Adjustment Scale (28) (Cronbach’s alpha in the current study = 
.83). 
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To assess the development of mental health disorders, we used established cut-offs on the 
Prodromal Questionnaire (23), Altman Mania Scale (26), PHQ (24), and GAD-7 (25). 
Participants were also asked at each assessment time-point whether they were in contact with 
mental health services, had received a mental health diagnosis, took medication for a mental 
health problem, or were currently receiving any other psychological therapy. 
 
Safety 
If the trial team was informed, we recorded the occurrence of any serious adverse events in trial 
participants, defined as: deaths; suicide attempts; serious violent incidents; admissions to secure 
units; and formal complaints about the online intervention.  
 
Analysis and sample size 
An outline of the analysis strategy was provided in the published trial protocol (14) and a full 
statistical analysis plan was agreed before the trial analysis (see online supplement). All the 
analyses were validated by a second statistician. Analyses were intention to treat and were 
carried out at the end of the last follow-up assessments (there were no interim analyses). Each 
continuous outcome was analysed using a linear mixed effects regression model to account for 
the repeated measures over time, and binary outcomes were analysed using a logistic mixed 
effects model. Mixed effects models are the recommended statistical technique for analysing 
clinical trials when outcomes are collected at repeated time points (29), and in this trial included 
outcome data available on all randomised participants at 3, 10, and 22 weeks. The method has 
the advantage of implicitly accounting for data missing at random. The estimated (adjusted) 
treatment differences from these analyses are therefore reported. The linear mixed effect 
models included the outcome as the response variable, time point, randomised group, and 
baseline score as fixed effects and random effects were estimated for student within university. 
An interaction between time and randomised group was modelled as a fixed effect to allow 
estimation of treatment effect at all three time points. Gender and course level were included as 
covariates in the model. An unstructured variance-covariance matrix was used to model the 
within-subject error correlation structure. Results are presented as mean adjusted differences in 
scores between the randomised groups, with 95% confidence intervals (CI) and associated two-
sided p-value. The normality assumption of the residuals was confirmed for each outcome. No 
deviations from normality were apparent and therefore maximum likelihood estimates were 
reported. Sensitivity analyses (pattern mixture models, inclusion of baseline covariates predictive 
of missing data, and imputation) were conducted for the three main outcomes, examining the 
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robustness of the results to different assumptions regarding missing data. Standardised effect 
sizes were calculated using Cohen’s d, dividing the treatment effect by the shared standard 
deviation at baseline. Similar logistic mixed effects models were used for the secondary binary 
outcomes. 
To test the mediation hypotheses, we determined the extent of mediation of the 3 week and 10 
week insomnia scores on the 10 week paranoia and hallucination outcomes. The approach used 
was similar to the approach of Baron and Kenny (30, 5), but made use of linear mixed effects 
models at each step. The approach involved four steps and three separate model fits. In two 
separate linear mixed effects models, the intervention was first shown to be correlated with the 
outcome, and, secondly, with the mediator. Then the data were fitted to a third model with the 
outcome as the response and both the intervention and mediator as covariates. The parameters 
were extracted as per Baron and Kenny (30) to obtain the total, direct, and indirect effects, and 
finally the percentage mediation was determined. In all models, baseline levels of both the 
outcome and mediator were included as covariates. This is similar to the mediation analysis in 
Freeman et al (31), but made use of linear mixed effects models to account for repeated 
measurements, rather than through structural equation modelling. 
The sample size was calculated on the basis of change in paranoia, since there should be lower 
change in psychotic experiences compared to insomnia. Based on the standard deviations 
observed from a previous study for the GPTS (SD=10.4) (32), a total sample size of 2614 (i.e. 
1307 per group) would provide 90% power to detect a small effect size, a standardised mean 
difference of 0.15, in paranoia, whilst accounting for a high level of expected attrition (40%). In a 
study amendment, the sample size was increased, due to a higher than initially expected drop-
out rate. 
 
Role of the funding source 
The funder had no role in study design, data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full access to all the data in the study and 
had final responsibility for the decision to submit for publication. 
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RESULTS 
 
Full details of the sample, missing data patterns, sensitivity analyses, and all other analyses are 
available in the online supplementary data analysis report. 
 
The sample 
The baseline characteristics of the participants are summarised in Table 1. The sample was 
predominately female, studying for their first university degree, and two-thirds were of White 
British ethnicity. One fifth of the participants were in contact with mental health services. The two 
randomised groups were well-matched at baseline. 
During the course of the study there is a high level of drop out from the study assessments 
(50%), which is greater in the treatment group than in the control group, with this figure and 
pattern almost identical to the most comparable previous study (12). The baseline scores for the 
three primary outcomes (insomnia, paranoia, hallucinations) were not associated with later 
missingness (see Table 1 in the supplementary data analysis report). Compared with 
participants who remained in the study, participants who dropped out from both randomised 
groups were younger in age and more likely to be male. For the secondary measures, ISI, PHQ-
9, AMS, and WSAS scores were slightly higher, and the WEMWBS score slightly lower, in the 
missing groups compared to the nonmissing groups. 
Treatment uptake was also limited. In the intervention arm, 1302 (68.9%) participants logged on 
for at least one treatment session. 953 (50.4%) participants accessed two sessions, 672 (35.5%) 
participants accessed three sessions, 497 (26.3%) participants accessed four sessions, 390 
(20.6%) participants accessed five sessions, and 331 (17.5%) participants accessed six 
sessions. Of those who started the programme, 672 (35.5%) participants accessed three or 
more sessions. 
 
------------------------------- 
Table 1 about here 
------------------------------- 
 
  
The effects of improving sleep on mental health 
13 
 
Primary outcomes 
The outcomes for the primary measures are shown in Table 2. In comparison to the control 
group, the sleep treatment is associated with significant reductions, at all time points, in 
insomnia, paranoia, and hallucinations. After treatment the reduction in insomnia is large, while 
the reduction in psychotic experiences is small. After treatment, 454 (61.9%) of 733 individuals 
in the treatment group and 326 (28.5%) of 1142 individuals in the control group now scored 
outside the clinical cut-off used for trial entry. The treatment differences are robust to the three 
different types of sensitivity analyses for missing data that were conducted (see online data 
analysis report). A conservative imputation (given the general improvement in scores in both 
groups) of missing data was used, whereby the last available measurement for a participant was 
imputed for all further missing measurements of that participant. All three primary outcome 
differences remained significant with last observation carried forward imputations. Treatment 
differences also remained consistent with the primary analysis when we repeated the main 
analyses covarying for baseline variables which predicted missingness for each outcome. We 
also used pattern mixture models. Treatment differences would still be significant assuming the 
missing individuals in the treatment arm had outcome scores two points worse for insomnia and 
paranoia, and one point worse for hallucinations (predictably the hallucination scale scores are 
much lower than for the other two outcome variables). 
The mediation analyses are summarised in Table 3. Change in sleep over three weeks 
explained 30% of the intervention effect on paranoia at 10 weeks, with change in sleep over 10 
weeks accounting for 58% of the treatment effect on paranoia. Change in sleep over three 
weeks explained 21% of the intervention effect on hallucinations at 10 weeks, with change in 
sleep over ten weeks accounting for 39% of the intervention effect on hallucinations. Hence 
early changes in sleep explain approximately half of the total sleep mediated change in 
psychotic experiences by the end of treatment. In comparison, parallel analyses in the reverse 
direction indicated that changes in psychotic experiences explained a much smaller percentage 
of variation in improvements in sleep. Specifically, when paranoia and hallucinations outcomes 
at three weeks were set as the mediators and the sleep outcome at 10 weeks as the main 
outcome, paranoia symptoms mediated just 3.8% of change in sleep and hallucinations 
mediated 3.4% of change in sleep. This lends further support to the causal pathway hypothesis 
proposed in this study. 
 
------------------------------------------ 
Tables 2 and 3 about here 
------------------------------------------ 
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Secondary outcomes 
The outcomes for the secondary measures are shown in Table 4. The large improvement in 
insomnia is confirmed with the ISI assessment. The sleep treatment also led to moderate 
improvements in depression, and small improvements in anxiety, psychosis prodromal 
symptoms, nightmares, psychological well-being, and functioning. All these improvements were 
maintained over time. Those randomised to the sleep treatment were also less likely to meet 
criteria over the course of the trial for a depressive episode, anxiety disorder, or ultra high risk of 
psychosis. However there were no differences in contact with mental health services. Further, 
the sleep treatment led to a small, sustained increase in symptoms of mania. There was also a 
greater risk with the sleep treatment of meeting criteria for a manic episode. 
 
------------------------------- 
Table 4 about here 
------------------------------- 
 
Adverse events 
No adverse events were reported to the trial team.  
 
 
DISCUSSION 
We wished to investigate the effects on mental health of reducing sleep difficulties. The first 
necessary stage was for the intervention to reduce insomnia. This was achieved. A large effect 
size reduction was found with the digital CBT intervention in a large student population. But it 
was the consequent effects on psychotic experiences that the trial was designed to establish. To 
our knowledge, OASIS is the largest randomised controlled trial of a psychological intervention 
for a mental health problem. Students randomised to the sleep intervention showed small, 
sustained reductions in paranoia and hallucinations. This is strong evidence that disrupted sleep 
has a contributory causal role in the occurrence of these psychotic experiences in a specific 
population of young adults. The mediation analyses supported this interpretation: improvements 
in sleep accounted for almost 60% of the change in paranoia post-treatment, for example. 
Insomnia may not be the largest cause of psychotic experiences but it is not an epiphenomenon. 
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Hence the study adds substantially to our understanding of the causes of psychotic experiences 
and indicates a promising route into the early treatment of psychotic problems. 
The focus on a sleep intervention in a young adult population is important. Young people with 
incipient disorders may be very reluctant to seek help for psychiatric problems. Trouble sleeping 
is a common complaint with little stigma. Hence, it provides a much more acceptable focus for a 
first step in a care pathway. There were added benefits from the digital sleep treatment. 
Depression in particular, but also anxiety, psychological well-being, nightmares, and perceived 
functioning all improved. The effects on anxiety and depression are consistent with a recent 
meta-analysis (33). Those who received the sleep treatment in the trial were less likely to report 
symptoms at a level that met criteria for ultra high risk of psychosis, depression, or anxiety 
disorder. At baseline the level of positive screens for psychosis risk with the Prodromal 
Questionnaire was high, comparable to the rates found with this questionnaire for adolescents 
referred to treatment services (34); this high rate will reflect the well-established associations of 
sleep difficulties with psychotic experiences (2, 3, 7, 8) (i.e. that participants have been selected 
for insomnia and therefore will score higher on psychosis measures) but also the limitations of 
brief self-report questionnaires for assessing psychosis risk. However in the trial there was no 
evidence that the sleep treatment affected contact with mental health services. Most participants 
were not in contact with these services so a longer follow-up period may be needed to truly test 
such effects. Further, there was an increase in manic symptoms associated with the sleep 
treatment. This may be due to an actual increase in problematic manic symptoms or it may 
simply reflect the overall increase in psychological well-being in the sample since the 
questionnaire domains concern cheerfulness, self-confidence, reduced need for sleep, increase 
in activity levels, and talkativeness. The Altman scale has recently been found to correlate poorly 
with self-ratings of elation (35). 
 
Are the study results generalizable beyond a student population? We consider that the results 
are very likely to apply to the wider adult population. We used a treatment developed for adults, 
which was not modified for students. The large treatment reduction in insomnia for the students 
is very similar to that found in trials with general adult populations (10, 11, 36), while previous 
studies with community samples have shown self-help sleep treatment to reduce anxiety and 
depression (36, 37). Nonetheless, only a direct comparison in a trial can definitively determine 
the generalisablilty of our findings. Although not the main objective of the study, the trial does 
indicate that the provision of internet-delivered CBT for insomnia to university students is likely to 
lead to large reductions overall in insomnia, and smaller reductions in a number of other mental 
health symptoms, with benefits for positive psychological well-being too. Tailoring of the 
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intervention specifically for this population could enhance engagement and outcome effects. 
Support to complete the intervention may well be helpful too. 
 
The OASIS study is a well-powered, randomised controlled trial, informed by the causal 
inference literature, but there are a number of limitations. First, the study relied on self-report 
questionnaires, albeit validated in their development against clinical interviews. Similar change 
captured in rater assessed measures would have strengthened the confidence in the study 
results. Second, the sample tested were predominately in the non-clinical range of psychotic 
experiences, limiting the conclusions to the less severe end of the psychosis spectrum. Third, 
the participants were self-selecting in responding to the invitation, which will have affected the 
representativeness of the sample. Access to the study was via an Internet webpage, which is a 
simpler process than obtaining treatment from clinical services. The whole study could be 
completed in the privacy of the home, meaning that there were far fewer barriers to participation 
than conventional patient trials. Fourth, the extent to which the results will generalise to the rest 
of the general population is not known. Even within the student population we do not know the 
representativeness of the participants. Fifth, bias in the outcome results will have been 
introduced due to the high drop-out rate, especially in the treatment group, which is similar to 
comparable online studies (12). The results did remain robust against conservative assumptions 
in the sensitivity analyses about those who dropped out, but it is notable that treatment effects 
were greater for those who completed the sleep treatment. Finally, the causal argument rests on 
the plausible assumption that the sleep treatment first changes levels of insomnia, since that 
was the topic of the intervention, but the mediation analyses in this trial based on ten week 
outcomes cannot fully capture the temporal order of changes or rule out reverse causation. We 
were able to show a significant level of mediation based on the 3 week insomnia score as a 
mediator, while evidence for reverse causation was limited, which does follow the predicted 
temporal causal pathway. In reality, it is difficult in a clinical trial to capture potential temporal 
changes between mediator and outcomes, since improvement in paranoia and hallucinations is 
likely to closely parallel the improvement in sleep. 
 
The work can be taken forward. Determining the mechanisms linking insomnia to psychotic 
experiences will shed further light on the causes of psychosis and potentially enable treatment 
improvement (3, 13). Of great clinical interest will be the evaluation of the effects of improving 
sleep for patients attending clinical services with ultra high risk of psychosis, or established 
clinical psychotic experiences, or at the early stages of relapse. Our experience is that patients 
with psychosis value their sleep difficulties being appropriately addressed, that this enhances 
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engagement with other treatments, and that better sleep can contribute to a reduction in 
psychotic experiences. Further, there is a challenge in mental health services regarding 
intervention for early, relatively non-specific presentations and proper sleep treatment may prove 
a sensible first response. Overall, this trial indicates to us the importance of sleep difficulties for 
mental health in the general population and the need for a reconsideration in clinical services of 
the priority given to improving sleep. 
 
 
Research in context 
Evidence before this study 
If insomnia is a contributory cause of psychotic experiences then the key test is whether 
improving sleep leads to a reduction in psychotic experiences. We therefore searched for 
randomised controlled studies that set out to reduce insomnia and examine the effects on 
psychotic experiences. On the 23rd June 2017 we searched the entire archive (i.e. using no date 
restrictions) of PubMed (https://www.ncbi.nlm.nih.gov/pubmed) for: (Sleep OR Insomnia) AND 
(Delus* OR Hallucinat* OR Psychosis OR Psychotic OR Schizophren*) AND (CBT OR hypnotic 
OR medication) AND (Random* OR RCT). 130 papers were identified. There were only two 
randomised controlled trials that tested the effects of sleep treatment on psychotic experiences, 
with the larger of the trials being our own with 50 patients with schizophrenia or related 
disorders. These trials were underpowered to determine with any precision the potential link 
between insomnia and psychotic experiences. 
Added value of this study 
We conducted what may be the largest randomised controlled test to date of a psychological 
treatment. It is the first study adequately powered to determine the effects of treating sleep 
dysfunction on psychotic experiences. It shows very clearly that treating insomnia in students 
leads to a reduction in psychotic experiences. A mediation analysis supports this interpretation. 
Further, the trial is consistent with a small number of other randomised controlled trials that 
indicate multiple other benefits for mental health of treating sleep problems. 
Implications of all the available evidence 
Sleep disruption may have a contributory causal role in the occurrence of psychotic experiences 
and a wide range of other mental health problems. Adequately powered tests in other 
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populations would be helpful, but research is accumulating indicating that the treatment of 
disrupted sleep requires a higher priority in mental health provision. 
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Table 1. Baseline information. 
Baseline Characteristics Control (n= 1864) Treatment (n=1891) 
Mean age in Years (SD)                24.6 (7.6) 24.8 (7.7) 
Mean total UCAS points  (SD)                               753.0 (517.3) 720.8 (456.3) 
Male 
Female 
Other 
530 (28.4%) 
1315 (70.6%) 
19 (1.0%) 
513 (27.1%) 
1361 (72.0%) 
17 (0.9%) 
Undergraduate student 
Postgraduate student 
Other 
1352 (72.5%) 
480 (25.8%) 
32 (1.7%) 
1389 (73.5%) 
473 (25.0%) 
29 (1.5%) 
White British 
White Irish 
White Other 
Mixed – White/Caribbean 
Mixed – White/African 
Mixed – White/Asian 
Mixed- Other 
Asian Indian 
Asian Pakistani 
Asian Bangladeshi 
Asian – Chinese 
Asian – Other 
Black – African 
Black – Caribbean 
Black – Other 
Arab 
Other 
1212 (65.0%) 
32 (1.7%) 
284 (15.3%) 
13 (0.7%) 
9 (0.5%) 
31 (1.7%) 
36 (1.9%) 
26 (1.4%) 
23 (1.2%) 
9 (0.5%) 
95 (5.1%) 
25 (1.3%) 
26 (1.4%) 
10 (0.5%) 
2 (0.1%) 
12 (0.6%) 
19 (1%) 
1265 (66.9%) 
27 (1.4%) 
261 (13.8%) 
11 (0.6%) 
13 (0.7%) 
27 (1.4%) 
29 (1.5%) 
43 (2.3%) 
22 (1.2%) 
7 (0.4%) 
73 (3.9%) 
32 (1.7%) 
23 (1.2%) 
17 (0.9%) 
3 (0.2%) 
14 (0.7%) 
24 (1.3%) 
Insomnia (SCI-8) mean score (SD) 10.1 (4.3) 9.9 (4.3) 
Paranoia (GPTS) mean score (SD) 24.8 (11.6) 25.4 (11.9) 
Hallucinations (SPEQ) mean score (SD) 5.3 (6.9) 5.3 (6.4) 
Insomnia (SCI-9) mean score (SD) 12.1 (4.9) 11.9 (4.8) 
Insomnia (ISI) mean score (SD) 15.3 (4.0) 15.4 (3.9) 
Nightmares (DDNSI) mean score (SD) 8.1 (8.2) 7.7 (7.8) 
Prodromal psychosis (PQ-16) mean score (SD) 4.9 (3.4) 4.8 (3.3) 
Depression (PHQ-9) mean score (SD) 12.7 (5.9) 12.9 (5.8) 
Anxiety (GAD-7) mean score (SD) 9.0 (5.6) 9.4 (5.6) 
Mania (Altman) mean score (SD) 3.5 (3.0) 3.5 (3.0) 
Functioning (WSAS) mean score (SD) 17.7 (7.6) 17.6 (7.6) 
Well-being (WEMWBS) mean score (SD) 37.9 (8.8) 37.8 (8.5) 
Ultra high risk of psychosis (PQ-16) Cut-off 
(6+) 
Above 
Below 
 
706 (37.9%) 
1158 (62.1%) 
 
711 (37.6%) 
1180 (62.4%) 
Depressive disorder (PHQ-9) Cut-off (10+) 
Above 
Below 
 
1238 (66.4%) 
626 (33.6%) 
 
1286 (68.0%) 
605 (32.0%) 
Anxiety disorder (GAD-7) Cut-off (10+) 
Above 
Below 
 
781 (41.9%) 
1083 (58.1%) 
 
880 (46.5%) 
1011 (53.5%) 
Mania disorder (Altman) Score Cut-off (6+) 
Above 
Below 
 
422 (22.6%) 
1442 (77.4%) 
 
413 (21.8%) 
1478 (78.2%) 
Contact with mental health services 
Yes 
 
328 (17.6%) 
 
346 (18.3%) 
Table
No 1536 (82.4%) 1545 (81.7%) 
Any psychiatric Diagnosis 
Yes 
No 
 
590 (31.7%) 
1274 (68.3%) 
 
641 (33.9%) 
1250 (66.1%) 
Previous diagnosis of a sleep disorder 
Yes  
No 
 
93 (5.0%) 
1771 (95.0%) 
 
96 (5.1%) 
1795 (94.9%) 
Any psychiatric Medication 
Yes 
No 
 
433 (23.2%) 
1431 (76.8%) 
 
460 (24.3%) 
1431 (75.7%) 
Specific medication for a sleep disorder 
Yes 
No 
 
51 (2.7%) 
1813 (97.3%) 
 
55 (2.9%) 
1836 (97.1%)) 
Psychological Therapy 
Yes 
No 
 
146 (7.8%) 
1718 (92.2%) 
 
135 (7.1%) 
1756 (92.9%) 
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Table 4. Secondary outcome results. 
 Insomnia (ISI) 10 Weeks Insomnia (ISI) 22 Weeks 
 Control 
n=1142 
Treatment 
n=733 
Control 
n=970 
Treatment 
n=603 
Unadjusted mean (standard 
deviation) 
12.95 
(5.27) 
9.23 (5.18) 12.17 
(5.29) 
8.62 (5.48) 
Adjusted difference* (95% 
confidence interval), d† 
-3.72 (-4.16; -3.29), 0.94 -3.40 (-3.87; -2.93), 0.86 
p-value <0.0001 <0.0001 
 Nightmares (DDNSI) 10 Weeks Nightmares (DDNSI) 22 Weeks 
 TAU 
n=1142 
Treatment 
n=733 
TAU 
n=963 
Treatment 
n=599 
Unadjusted mean (standard 
deviation) 
7.35 (7.85) 5.47 (6.91) 7.32 (7.93) 5.09 (6.66) 
Adjusted difference* (95% 
confidence interval), d† 
-1.63 (-2.16; -1.10), 0.20 -1.84 (-2.41; -1.26), 0.23 
p-value <0.0001 <0.0001 
 Prodromal psychosis (PQ-16) 10 
Weeks 
Prodromal psychosis (PQ-16) 
22 Weeks 
 TAU 
n=1142 
Treatment 
n=733 
TAU 
n=971 
Treatment 
n=603 
Unadjusted mean (standard 
deviation) 
4.35 (3.71) 3.37 (3.29) 4.05 (3.83) 3.14 (3.24) 
Adjusted difference* (95% 
confidence interval), d† 
-0.81 (-1.03; -0.60), 0.24 -0.74 (-0.98; -0.51), 0.22 
p-value <0.0001 <0.0001 
 Depression (PHQ-9) 10 Weeks Depression (PHQ-9) 22 Weeks 
 TAU 
n=1142 
Treatment 
n=733 
TAU 
n=971 
Treatment 
n=602 
Unadjusted mean (standard 
deviation) 
11.27 
(6.72) 
8.44 (6.16) 10.34 
(6.79) 
8.00 (6.54) 
Adjusted difference* (95% 
confidence interval), d† 
-2.83 (-3.30; -2.35), 0.48 -2.44 (-2.95; -1.94), 0.42 
p-value <0.0001 <0.0001 
 Anxiety (GAD-7) 10 Weeks Anxiety (GAD-7) 22 Weeks 
 TAU 
n=1142 
Treatment 
n=733 
TAU 
n=971 
Treatment 
n=603 
Unadjusted mean (standard 
deviation) 
8.35 (6.06) 6.53 (5.40) 7.67 (6.10) 6.14 (5.41) 
Adjusted difference* (95% 
confidence interval), d† 
-1.86 (-2.29; -1.43), 0.33 -1.56 (-2.01; -1.10), 0.28 
p-value <0.0001 <0.0001 
 Mania (Altman) 10 Weeks Mania (Altman) 22 Weeks 
 TAU 
n=1142 
Treatment 
n=733 
TAU 
n=971 
Treatment 
n=603 
Unadjusted mean (standard 
deviation) 
2.97  (3.03) 3.77 (3.33) 2.92 (3.06) 3.57 (3.41) 
Adjusted difference* (95% 
confidence interval), d† 
0.93 (0.67; 1.19), -0.31 0.75 (0.46; 1.03), -0.25 
p-value <0.0001 <0.0001 
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 Functioning (WSAS) 10 Weeks Functioning (WSAS) 22 Weeks 
 TAU 
n=1142 
Treatment 
n=733 
TAU 
n=971 
Treatment 
n=603 
Unadjusted mean (standard 
deviation) 
15.92 
(8.89) 
11.43 (8.37) 14.92 
(9.17) 
10.25 (8.30) 
Adjusted difference* (95% 
confidence interval), d† 
-4.36 (-5.03; -3.69), 0.58 -4.33 (-5.05; -3.62), 0.57 
p-value <0.0001 <0.0001 
 Well-being (WEMWBS) 10 
Weeks 
Well-being (WEMWBS) 22 
Weeks 
 TAU 
n=1142 
Treatment 
n=733 
TAU 
n=971 
Treatment 
n=603 
Unadjusted mean (standard 
deviation) 
38.73 
(9.78) 
40.92 (9.63) 39.63 
(10.19) 
42.12 (10.36) 
Adjusted difference* (95% 
confidence interval), d† 
2.47 (1.72; 3.22), 0.29 2.78 (1.97; 3.60), 0.32 
p-value <0.0001 <0.0001 
Dichotomous outcomes 
 Ultra high risk of psychosis 
(PQ16) 10 Weeks 
Ultra high risk of psychosis 
(PQ16) 22 Weeks 
 TAU 
n=1142 
Treatment 
n=733 
TAU 
n=971 
Treatment 
n=603 
Adjusted odds ratio‡ (95% 
confidence interval) 
0.26 (0.15; 0.46) 0.33 (0.18; 0.59) 
p-value <0.0001 0.00026 
 Mania (Altman) 10 Weeks Mania (Altman) 22 Weeks 
 TAU 
n=1142 
Treatment 
n=733 
TAU 
n=971 
Treatment 
n=603 
Adjusted odds ratio‡ (95% 
confidence interval) 
2.01 (1.48; 2.73) 1.89 (1.34; 2.66) 
p-value <0.0001 0.00027 
 Depressive disorder (PHQ-9) 10 
Weeks 
Depressive disorder (PHQ-9) 22 
Weeks 
 TAU 
n=1142 
Treatment 
n=733 
TAU 
n=971 
Treatment 
n=603 
Adjusted odds ratio‡ (95% 
confidence interval) 
0.21 (0.14; 0.32) 0.32 (0.21; 0.48) 
p-value <0.0001 <0.0001 
 Anxiety disorder (GAD-7) 10 
Weeks 
Anxiety disorder (GAD-7) 22 
Weeks 
 TAU 
n=1142 
Treatment 
n=733 
TAU 
n=971 
Treatment 
n=603 
Adjusted odds ratio‡ (95% 
confidence interval) 
0.32 (0.21; 0.48) 0.42 (0.27; 0.64) 
p-value <0.0001 <0.0001 
 Contacted Mental Health 
Services  
10 Weeks 
Contacted Mental Health 
Services  
22 Weeks 
 TAU 
n=1142 
Treatment 
n=733 
TAU 
n=971 
Treatment 
n=603 
Adjusted odds ratio‡ (95% 1.19 (0.70; 2.04) 0.98 (0.55; 1.75) 
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confidence interval) 
p-value 0.52 0.94 
 Mental health diagnosis 10 
Weeks 
Mental health diagnosis 22 
Weeks 
 TAU 
n=1142 
Treatment 
n=733 
TAU 
n=971 
Treatment 
n=603 
Adjusted odds ratio‡ (95% 
confidence interval) 
1.33 (0.75; 2.37) 1.43 (0.78; 2.63) 
p-value 0.33 0.25 
 Psychiatric medication 10 
Weeks 
Psychiatric medication 22 
Weeks 
 TAU 
n=1142 
Treatment 
n=733 
TAU 
n=971 
Treatment 
n=603 
Adjusted odds ratio‡ (95% 
confidence interval) 
0.77 (0.47; 1.26) 0.96 (0.58; 1.59) 
p-value 0.30 0.86 
 Psychological Therapy  10 
Weeks 
Psychologial Therapy  22 
Weeks 
 TAU 
n=1142 
Treatment 
n=733 
TAU 
n=971 
Treatment 
n=603 
Adjusted odds ratio‡ (95% 
confidence interval) 
1.27 (0.48; 3.35) 0.41 (0.11; 1.58) 
p-value 0.63 0.20 
 
* Linear mixed effects model adjusted for gender, student status, week and interaction of week 
with randomisation, and including a random effect for student within university. Covariance 
matrix of within subject measurements unstructured. 
† d = standardised effect size (Cohen’s d) 
‡ Logistic mixed effects model adjusted for gender, student status, week and interaction of week 
with randomisation, and including a random effect for student within university. Covariance 
matrix of within subject measurements unstructured. 
 
 
 
Table 2. Primary outcome results.  
 Control 
n=1398 
Treatment 
n=1044 
Control 
n=1142 
Treatment 
 n=733 
Control 
 n=971 
Treatment 
 n=603 
 Insomnia (SCI-8) 
3 Weeks 
Insomnia (SCI-8) 
10 Weeks 
Insomnia (SCI-8) 
22 Weeks 
Unadjusted mean (standard 
deviation) 
12.34 
(5.85) 
14.96 
(5.80) 
13.31 
(6.45) 
18.08 
(6.66) 
14.43 
(6.71) 
19.27 
(7.13) 
Adjusted difference* (95% 
C.I.), d† 
2.62 (2.19; 3.06), 0.61 4.78 (4.29; 5.26), 1.11 4.81 (4.29; 5.33), 1.12 
p-value* <0.0001 <0.0001 <0.0001 
 Paranoia (GPTS) 
3 Weeks 
Paranoia (GPTS) 
10 Weeks 
Paranoia (GPTS) 
22 Weeks 
Unadjusted mean (standard 
deviation) 
24.63 
(11.82) 
22.61 
(9.89) 
23.84 
(12.16) 
21.06 
(9.08) 
23.84 
(12.68) 
20.75 
(9.19) 
Adjusted difference* (95% 
C.I.), d† 
-1.81 (-2.49; -1.13), 0.15 -2.22 (-2.98; -1.45), 0.19 -2.78 (-3.60; -1.96), 0.24 
p-value* <0.0001 <0.0001 <0.0001 
 Hallucinations (SPEQ) 
3 Weeks 
Hallucinations (SPEQ) 
10 Weeks 
Hallucinations (SPEQ) 
22 Weeks 
Unadjusted mean (standard 
seviation) 
5.06 
(6.89) 
4.06 
(5.84) 
4.89 
(7.24) 
3.12 
(5.12) 
4.71 
(7.43) 
2.87 
(5.45) 
Adjusted difference* (95% 
C.I.), d† 
-0.79 (-1.15; -0.42), 0.12 -1.58 (-1.98; -1.18), 0.24 -1.56 (-1.99; -1.14), 0.23 
p-value* <0.0001 <0.0001 <0.0001 
 
* Linear mixed effects model adjusted for gender, student status, week and interaction of 
week with randomisation, and including a random effect for student within university. 
Covariance matrix of within subject measurements unstructured. 
† d = standardised effect size (Cohen’s d) 
 
Table
Table 3. Mediation analysis* results (n=1718). 
 
  Total Effect 
 
Direct Effect 
 
Indirect Effect 
 
Percent 
mediated 
Outcome 
at week 10 
Mediator 
(SCI) 
Effect size - 
adjusted 
treatment 
difference 
(95% 
confidence 
interval) 
p Effect size - 
adjusted 
treatment 
difference (95% 
confidence 
interval) 
p Effect size -
adjusted 
treatment 
difference (95% 
confidence 
interval) 
p  
Paranoia 
(GPTS)  
Insomnia 
at Week 3 
-2.27 
(-3.03; -1.51) 
<0.0001 -1.85 
(-2.66; 1.04) 
<0.0001 -0.67 
(-0.86; -0.48) 
<0.0001 29.5% 
 Insomnia 
at Week 
10 
-2.27 
(-3.03; -1.51) 
<0.0001 -0.97 
(-1.80; -0.14) 
<0.0001 -1.31 
(-1.60; -1.02) 
<0.0001 57.8% 
         
Hallucinati
ons (SPEQ) 
Insomnia 
at Week 3 
-1.60 
(-2.00; -1.20) 
<0.0001 -1.36 
(-1.79; -0.94) 
<0.0001 -0.33 
(-0.43; -0.23) 
<0.0001 20.7% 
 Insomnia 
at Week 
10 
-1.60 
(-2.00; -1.20) 
<0.0001 -0.90 
(-1.34; -0.46) 
<0.0001 -0.62 
(-0.78; -0.46) 
<0.0001 38.6% 
 
*Outcome and mediators modelled by means of linear mixed effects models and the total, direct, 
and indirect effects determined using the Baron and Kenny (30) approach. The effect size is the 
adjusted treatment difference (i.e. non-standardised treatment difference). 
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